After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

Advantages

Targeting

Targeted killing of tumor cells, no effect on the normal body, higher killing efficiency
High efficiency

CTL cultured in vitro has powerful targeted killing effect, definite curative effect, and broad spectrum of tumor treatment
safety

Safe and reliable, no side effects
Reversing resistance

Reversible resistance to small molecule targeted drugs
Convenience

The clinical treatment cycle is short, one treatment is (12-14 days)
Preventive treatment

Treat some precancerous lesions to play a preventive and therapeutic role

Indications and Protocols

ACTL immunotherapy has a wide range of indications. Cancer patients can receive treatment if they meet the following conditions:

Tumor tissue MHC-I molecules (HLA-I antigen) are positive;

At least one tumor-associated antigen is positive (please see "Introduction to rAAV products carrying tumor-associated antigens")

Normal liver and kidney function;

No severe anemia;

Stop chemotherapy and radiotherapy, and the number of peripheral blood cells is not low;

The larger tumor tissue has been removed;

No serious allergies.

I. Patients with stage II tumors

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
III. Patients with stage IV tumors

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
Patients who have finished radiotherapy and chemotherapy

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
Patients receiving radiotherapy and chemotherapy

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
Patients with severe disease and rapid progress

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

ACTL Immunotherapy Research Application Form ACTL Immunotherapy Patient Screen Cretiria List of Antigens

Case Studies

My father's lung cancer made me feel that life is so vulnerable-a true story from the patient's family!

According to statistics from the National Health and Fam...

Category：Lung Cancer

Using ACTL technology alone to treat lung cancer brain metastases, the effect is obvious!

Lung cancer is one of the malignant tumors with the fastest...

Category：Lung Cancer

ACTL broke out "power of the wild", fighting cancer alone, prolonging patients' lives

In 2003, the ACTL technical team received a doctor, but...

Category：Lung Cancer

7 ACTL treatments to clear HPV infection

Cervical cancer is currently one of the few cancers that ca...

Category：Cervical Cancer

After the long dark night, the sunrise at dawn will be more beautiful——The self-report of cervical cancer patients

Compared to the pain, what is more painful than the pain is...

Category：Cervical Cancer

It’s you who continued my beautiful life——Sharing the truth of patients with occult advanced breast cancer

Cancer, are you scared when you hear these two words? I do...

Category：Breast Cancer

"Private Custom" ACTL Treatment of Breast Cancer

Breast cancer is the number one common malignant tumor in w...

Category：Breast Cancer

Breast cancer didn't make me feel bad, it made me stronger

"I really envy your current state, as indifferently as a br...

Category：Breast Cancer

Revealing the culprit of men’s health, "prostate cancer", men cannot afford to hurt!

Prostate cancer is one of the main malignant tumors for mid...

Category：Prostate Cancer

ACTL treatment significantly reduces PSA in prostate cancer

After treatment with hormone therapy and chemotherapy, Mr....

Category：Prostate Cancer

ACTL technology treats prostate cancer, showing bright prospects!

In recent years, the incidence of prostate cancer has risen...

Category：Prostate Cancer

Family love gave me confidence, and ACTL treated my colon cancer

Looking back on the days when I was suffering from cancer,...

Category：Colon Cancer

ACTL technology treatment allows me to overcome cancer and regain my life

For a patient with advanced colon cancer like me, it really...

Category：Colon Cancer

Accidental bleeding was told that he was suffering from colorectal cancer, and he strengthened himself and finally repelled the cancer!

"When I know that I have cancer, I have two choices in m...

Category：Colon Cancer

ACTL technology security

ACTL security

ACTL technology is safe. The gene carrier it uses is adeno-associated virus (AAV). After more than 20 years of extensive research around the world, it has been proved that adeno-associated virus (AAV) is a non-lethal virus. Will cause any physiological or pathological changes, which has been recognized by the medical community. The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) have announced for many years that AAV is the safest viral vector for gene therapy. Epidemiological surveys and laboratory studies conducted by the University of Arkansas School of Medicine in conjunction with other American universities have shown that AAV is not only non-pathogenic, but also can inhibit the growth of cervical cancer and breast cancer, and can inhibit human papillary virus and hepatitis B The replication of viruses and viruses such as HIV. ACTL technology is safe. The gene carrier it uses is adeno-associated virus (AAV). After more than 20 years of extensive research around the world, it has been proved that adeno-associated virus (AAV) is a non-lethal virus. Will cause any physiological or pathological changes, which has been recognized by the medical community. The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) have declared for many years that AAV is the safest viral vector for gene therapy. Epidemiological surveys and laboratory studies conducted by the University of Arkansas School of Medicine in conjunction with other American universities have shown that AAV is not only non-pathogenic, but also can inhibit the growth of cervical cancer and breast cancer, and can inhibit human papillary virus and hepatitis B The replication of viruses and viruses such as HIV.

【 Read More 】

ACTL technology treatment process

Technology R & D

At present, the first-generation ACTL technology is widely used in clinical practice. Its technical principles and technical advantages have been discussed in detail in this research report. The company has successfully developed the second, third, and fourth generations on the basis of it. The characteristics of the first and fifth generation ACTL technologies are as follows:

Second generation ACTL technology

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
Third-generation ACTL technology

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
Fourth generation ACTL technology

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;
Fifth generation ACTL technology

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

Patents of ACTL Immunotherapy

Patient ID Patent

US6153436A Method of gene delivery using wild type adeno-associated viral (AAV) vectors with insertions
US6495361B1 Method of producing infectious papillomavirus in placental cells
US6506600B2 Secreting products from skin by adeno-associated virus (AVV) gene transfer
US6884602B2 Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
EP1206563B1 Genetically altered dendritic cells transduced with adeno-associated virus (AAV), methods of producing said cells and uses thereof
200880012949.6 A group of recombinant adeno-associated virus vectors and its construction method and application
201110125660.9 A Her-2/neu recombinant adeno-associated virus vector and its construction method and application
201110125697.1 A BA46 recombinant adeno-associated virus vector and its construction method and application
201110125665.1 A LMP-1 recombinant adeno-associated virus vector and its construction method and application
201110125683.X An AFP recombinant adeno-associated virus vector and its construction method and application
201110125603.0 A PSA recombinant adeno-associated virus vector and its construction method and application
201110125643.5 A CEA recombinant adeno-associated virus vector and its construction method and application
201110125632.7 A PSMA recombinant adeno-associated virus vector and its construction method and application
US6153436A Method of gene delivery using wild type adeno-associated viral (AAV) vectors with insertions

【 Read More 】

Publications

ACTL effectiveness and AAV safety clinical trial literature (1)[ Link ]
ACTL effectiveness and AAV safety clinical trial literature (2)[ Link ]
ACTL effectiveness and AAV safety clinical trial literature (3)[ Link ]
ACTL effectiveness and AAV safety clinical trial literature (4)[ Link ]
ACTL effectiveness and AAV safety clinical trial literature (5)[ Link ]
ACTL effectiveness and AAV safety clinical trial literature (6)[ Link ]

【 Read More 】

Milestones

2020s

In September 2020, the State Intellectual Property Office granted Shenzhen Yishi Kangning Biotechnology Co., Ltd. an invention patent for "A Recombinant Adeno-Associated Virus Vector Carrying Tumor-Testis Antigen 10 Gene and Its Application Value". This patent is Yishi Kangning. Obtained the 14th Chinese invention patent.

2020s

Renamed Shenzhen Experimental Center to Shenzhen ACTL Cell Preparation Center

select September March

2019s

In September 2019, 21 national ministries and commissions jointly issued a document: "Action Program for Promoting the High-quality Development of the Health Industry (2019-2022)". ACTL technology ushered in new developments.

select September

2018s

At present, there are more than 40 kinds of adeno-associated virus products developed, and 13 domestic invention patents, 3 American invention patents and 1 European invention patent have been obtained.

select December

2017s

The Zhejiang prostate cancer multi-center clinical research project was launched in Zhejiang Provincial People's Hospital.

2017s

The Japan Cell Therapy Association began to discuss cooperation with the company on the introduction of ACTL treatment technology projects.

2017s

Shenzhen Yishi Kangning Biotechnology Co., Ltd. and Singapore's REGENE GROUP ACTL technology project cooperation signing was successfully held to establish an anti-cancer biological treatment center in Singapore. It marks that ACTL treatment technology goes abroad.

Shandong Province Colorectal Cancer Multi-center Clinical Research Project was approved by Shandong Provincial Health and Family Planning Commission.

select February March April

2016s

The company won the national high-tech enterprise certification.

The company’s ACTL technology won the second prize of the “2015 Shenzhen Science and Technology Award” for the Science and Technology Progress Award.

2016s

Approved by Jiangsu Provincial Health and Family Planning Commission, led by Jiangsu Provincial People’s Hospital, combined with 18 hospitals in Jiangsu Province ---ACTL targeted anti-tumor cell immunotherapy combined with TKI for the treatment of advanced EGFR sensitive mutation-positive non-small cell lung cancer The multi-center Phase II clinical study was officially launched. This is the first clinical trial of targeted T cell immunotherapy approved by the government in my country.

The company successfully passed the AAA credit rating of China International Electronic Commerce Center with the credit code: BCP08924329.

2016s

As of the end of April, thousands of cancer patients have received ACTL treatment and achieved good results.

The second-generation ACTL treatment technology has been successfully applied in clinical practice.

2016s

ACTL targeted anti-tumor cell immunotherapy combined with TKI for the treatment of advanced EGFR sensitive mutation-positive non-small cell lung cancer, a randomized, blank-controlled multi-center phase II clinical research project signing meeting was successfully held in Nanjing Zhongshan Hotel.

2016s

Three more invention patent applications entered the substantive examination stage of the National Patent Office, and the number of invention patents owned by the company continued to increase

2016s

The fifth generation of ACTL treatment technology began to develop

2016s

The two new antigen products have been successfully developed, and the number of ACTL technology products continues to increase, and the application areas are more extensive.

2016s

ACTL treatment technology was reviewed and approved by the Hainan Health and Family Planning Commission. In the same month, the ACTL Technical Treatment Center Base in Hainan Province officially launched the groundbreaking ceremony, striving to be completed and opened within one year.

2016s

As of the end of 2016, nearly 40 antigen products can be applied to various solid tumors and lymphomas such as lung cancer, bowel cancer, stomach cancer, liver cancer, breast cancer, cervical cancer, prostate cancer, etc.

The trademark "Iscoming" has completed the registration of trademarks of 1, 9, 10, 11, 12, 16, 18, 20, 21, 24, 28, 36, 37, 38, 39, 40, 41, 42, 45.

select January March April May June August September November December

2015s

Shenzhen Yishi Kangning Biological Technology Co., Ltd. was included in the key cultivation echelon of Shenzhen enterprises.

2015s

Beijing 307 Hospital published the clinical literature on the treatment of HPV-infected cervical cancer with ACTL technology in the 5th issue of "Chinese Journal of Cancer Biotherapy" in 2014, which has a profound impact on ACTL technology.

2015s

The company signed a strategic cooperation agreement with Peking University Shenzhen Hospital and began clinical application of ACTL technology.

Shenzhen Second Hospital started clinical application of ACTL technology.

2015s

After 8 months of treatment with ACTL technology and observation and evaluation, about 60% of advanced cancer patients with bone metastases have achieved CR, PR or SD. It shows that ACTL technology has great potential in the treatment of this field.

2015s

Two new antigen products have been successfully developed and applied in clinical practice, and the number of ACTL technology products continues to increase.

The fourth generation ACTL technology was successfully developed.

2015s

The "Clinical Observation of ACTL Combined with Chemotherapy in Treatment of Advanced Breast Cancer" published by the Huadu Hospital of Southern Medical University in Henan Medical Research, Volume 24, Issue 7, HENA, July 2015, has a clinical effective rate of 75%.

2015s

The company has passed ISO14001 environmental management system certification and OHSAS8001 occupational health and safety management system certification and obtained certification.

2015s

Three invention patent applications entered the substantive examination stage of the National Patent Office, and the number of invention patents owned by the company continued to increase.

The ACTL technique of systemic and local treatment for 6 cases of skin malignant tumors or metastatic lesions is effective. Among them, 3 patients with advanced malignant melanoma had not recurred until May 2017. ACTL treatment technology has added new usages.

2015s

The Guangxi Armed Police Corps Hospital started clinical application of ACTL technology.

select January February April May June July September October November

2014s

The clinical application of ACTL technology was officially launched in Zhuhai, Hebei, and Henan.

2014s

Huadu Hospital affiliated to Southern Medical University began clinical application of ACTL technology.

2014s

The Zhuhai Medical Association and the Zhuhai Anti-Cancer Association took the lead, and many hospitals including Zhongshan Tumor and Zhuhai People's Hospital successfully held the ACTL New Technology Academic Exchange Conference.

2014s

The project "Development of a new generation of targeted anti-breast cancer cell immunotherapy technology" was approved as a special project for the development of the biological industry in Shenzhen in 2014.

The fourth generation of ACTL treatment technology began to be developed.

2014s

Shenzhen Yishi Kangning Biotechnology Co., Ltd. became the governing unit of Shenzhen Life Science and Biotechnology Association;

The company held a number of ACTL academic exchange conferences in eastern Guangdong, which played an important role in clinical application of ACTL technology in eastern Guangdong.

The company was invited by the Shenzhen Science and Technology Innovation Commission and the Life Science and Biotechnology Association to participate in the formulation of the Shenzhen breast cancer industry roadmap.

2014s

The company moved to a new location: Nanshan High-tech Industrial Park Kexing Science Park, in accordance with US FDA standards, established a 1,100-square-meter GMP-compliant laboratory integrating R&D, production, and quality control.

The new antigen products CD20 and CD269 for hematological tumors have been successfully applied in clinical practice, and the field of ACTL treatment technology has continued to expand.

2014s

As of August 2014, more than 30 products of ACTL technology have been used clinically.

2014s

ACTL local + systemic therapy has been successfully used for liver cancer, pancreatic cancer, and breast cancer.

The company won the gold and silver awards for innovation achievements in the biological life and health industry.

2014s

The company passed the ISO9001 quality management system certification and obtained the certification.

2014s

The company was awarded the Shenzhen High-tech Enterprise Certificate.

select February March April May June July August September October December

2013s

The Affiliated Tumor Hospital of Sun Yat-sen University began clinical application of ACTL technology.

The second generation ACTL treatment technology was successfully developed.

2013s

ACTL technology and its products have been certified by the National Food and Drug Administration, China Food and Drug Control Research Institute, National Drug Safety Evaluation and Monitoring Center, Guangzhou General Medical Research Institute Drug Non-clinical Evaluation Research Center, and Guangzhou Microbiological Testing Center, marking the development of ACTL treatment technology Safety has been recognized by national authorities.

2013s

Started to develop the third-generation ACTL technology, which was successful after a few months.

The registration of 42 categories of "Yishekangning" trademark has been completed, the registration number is: 10551945

2013s

PLA 307 Hospital started clinical application of ACTL technology.

2013s

The registration of "Yishekang Ning" trademark registration in 44 categories is completed, the registration number is: 10551945 "ACTL" trademark registration is completed in categories 5, 10, 42, 44, the registration number of "ACTL" trademark 5 is: 10551949; "ACTL" trademark The registration number of category 10 is: 10551951; the registration number of category 42 of "ACTL" trademark is: "ACTL" trademark 10551946; the registration number of category 44 is: 10551954 "IMMUCLIN" trademark registration is completed for categories 5, 42, and 44, "IMMUCLIN" trademark The registration number of category 5 is: 10551950; the registration number of category 42 of "IMMUCLIN" trademark is: 10551947; the registration number of category 44 of "IMMUCLIN" trademark is 10551953

2013s

Four new antigen products have been successfully developed and applied to the clinic, and new members have been added to the products of ACTL treatment technology.

Tianjin Cancer Hospital began clinical application of ACTL technology.

2013s

Obtained 8 domestic related patent authorizations for ACTL technology (Chinese patent numbers: 200880012949.6, 201110125660.9, 201110125697.1, 201110125665.1, 201110125683.X, 201110125603.0, 201110125643.5, 201110125632.7).

2013s

"ACTL Targeted Cellular Immunotherapy Technology R&D and Application" was approved as "2013 Core Technology Breakthrough Funding Program Project in Nanshan District, Shenzhen";

Two new antigen products have been successfully developed and applied in clinical practice, and ACTL technology products continue to increase.

More than ten hospitals including Shenzhen Second Hospital and Henan Anyang Cancer Hospital have begun clinical application of ACTL technology.

2013s

4 cases of non-small cell lung adenocarcinoma patients with brain metastases received 4--6 ACTL treatments, of which 2 cases achieved complete response (CR), one case was partial response (PR), and the effect was significant. It shows that ACTL treatment technology can be used to treat malignant tumor metastases of the central nervous system.

2013s

Started to develop ACTL treatment technology and its products for hematological tumors, and succeeded a few months later.

select February March April May June July August September November December

2012s

Shenzhen Yishi Kangning Biotechnology Co., Ltd. was officially registered and established, marking the official start of clinical application and continued research and development of ACTL anti-tumor targeted cellular immunotherapy technology (ACTL) in China.

2012s

The preclinical study of ACTL treatment technology was officially launched.

2012s

ACTL treatment technology is included in the scope of Guangdong Medical Insurance.

2012s

ACTL treatment technology began to be clinically applied in the Cancer Center of Southern Medical University. It was the first cellular immunotherapy technology in the country to settle in a first-class tertiary hospital in the country, and it has achieved obvious effects in subsequent clinical practice, especially for advanced prostate cancer.

2012s

"ACTL Targeted Cellular Immunotherapy Technology R&D and Its Application" was approved as "Shenzhen and Nanshan District R&D Funding Project in 2012".

2012s

Peking University Cancer Hospital carried out a phase I safety study of ACTL treatment on 27 patients, and the patients were well tolerated. The literature was published in Clin Transl and translational Oncology, September 14, 2012, Issue 09.

2012s

As of the end of 2012, 21 antigen products have been successfully developed and produced, which are used in ACTL technology to treat lung cancer, bowel cancer, gastric cancer, breast cancer, prostate cancer and other malignant tumors.

select March May July August October November December